FibroGen, Inc (FGEN) Earns Buy Rating from Stifel Nicolaus

Stifel Nicolaus reaffirmed their buy rating on shares of FibroGen, Inc (NASDAQ:FGEN) in a research report sent to investors on Thursday morning. Stifel Nicolaus currently has a $80.00 target price on the biopharmaceutical company’s stock.

Several other research analysts have also recently commented on the stock. Jefferies Group LLC restated a buy rating and set a $75.00 target price on shares of FibroGen in a report on Tuesday, September 12th. William Blair reiterated an outperform rating on shares of FibroGen in a research note on Wednesday, August 9th. Leerink Swann reiterated an outperform rating and issued a $82.00 price target (up previously from $52.00) on shares of FibroGen in a research note on Tuesday, August 8th. Citigroup Inc. increased their price target on shares of FibroGen from $48.00 to $65.00 and gave the company a top pick rating in a research note on Tuesday, August 8th. Finally, BidaskClub cut shares of FibroGen from a strong-buy rating to a buy rating in a research note on Monday, July 31st. One research analyst has rated the stock with a sell rating, one has given a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The stock has an average rating of Buy and an average target price of $60.17.

Shares of FibroGen (NASDAQ:FGEN) traded up 0.58% on Thursday, reaching $52.40. 1,462,946 shares of the company traded hands. The stock’s market cap is $3.73 billion. The stock has a 50 day moving average of $43.31 and a 200 day moving average of $32.07. FibroGen has a 52-week low of $15.60 and a 52-week high of $52.70.

FibroGen (NASDAQ:FGEN) last announced its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.47) by ($0.01). FibroGen had a negative return on equity of 64.42% and a negative net margin of 105.59%. The business had revenue of $29.00 million for the quarter, compared to analyst estimates of $34.80 million. On average, analysts expect that FibroGen will post ($1.80) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “FibroGen, Inc (FGEN) Earns Buy Rating from Stifel Nicolaus” was originally published by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at https://www.truebluetribune.com/2017/09/17/fibrogen-inc-fgen-earns-buy-rating-from-stifel-nicolaus.html.

In other FibroGen news, Director Jorma Routti sold 12,000 shares of the stock in a transaction on Friday, September 1st. The shares were sold at an average price of $47.36, for a total value of $568,320.00. Following the completion of the sale, the director now owns 133,840 shares in the company, valued at $6,338,662.40. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Rory B. Riggs sold 25,000 shares of the stock in a transaction on Wednesday, September 13th. The shares were sold at an average price of $51.92, for a total transaction of $1,298,000.00. Following the completion of the sale, the director now owns 435,200 shares of the company’s stock, valued at approximately $22,595,584. The disclosure for this sale can be found here. In the last quarter, insiders sold 509,328 shares of company stock valued at $21,719,918. Corporate insiders own 14.90% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. SG Americas Securities LLC lifted its stake in shares of FibroGen by 6.5% during the 2nd quarter. SG Americas Securities LLC now owns 6,747 shares of the biopharmaceutical company’s stock worth $218,000 after buying an additional 412 shares during the last quarter. Cornerstone Capital Management Holdings LLC. lifted its stake in shares of FibroGen by 1.7% during the 2nd quarter. Cornerstone Capital Management Holdings LLC. now owns 29,090 shares of the biopharmaceutical company’s stock worth $939,000 after buying an additional 474 shares during the last quarter. Principal Financial Group Inc. lifted its stake in shares of FibroGen by 0.4% during the 1st quarter. Principal Financial Group Inc. now owns 136,045 shares of the biopharmaceutical company’s stock worth $3,354,000 after buying an additional 504 shares during the last quarter. Ameritas Investment Partners Inc. lifted its stake in shares of FibroGen by 15.4% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,218 shares of the biopharmaceutical company’s stock worth $169,000 after buying an additional 696 shares during the last quarter. Finally, Tudor Investment Corp ET AL lifted its stake in shares of FibroGen by 7.1% during the 2nd quarter. Tudor Investment Corp ET AL now owns 12,095 shares of the biopharmaceutical company’s stock worth $391,000 after buying an additional 799 shares during the last quarter. Institutional investors own 47.49% of the company’s stock.

About FibroGen

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Analyst Recommendations for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply